Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections

OBJECTIVES: The identification of the SARS-CoV-2 Omicron variants BA.1 and BA.2 immediately raised concerns about the efficacy of currently used monoclonal antibody therapies. Here, we analyzed the activity of Sotrovimab and Regdanvimab, which are used in clinics for treatment of moderate to severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Dichtl, Stefanie, Zaderer, Viktoria, Kozubowski, Viktoria, Abd El Halim, Hussam, Lafon, Eliott, Lanser, Lukas, Weiss, Günter, Lass-Flörl, Cornelia, Wilflingseder, Doris, Posch, Wilfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556863/
https://www.ncbi.nlm.nih.gov/pubmed/36250084
http://dx.doi.org/10.3389/fmed.2022.1005589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556863/
https://www.ncbi.nlm.nih.gov/pubmed/36250084
http://dx.doi.org/10.3389/fmed.2022.1005589

Ejemplares similares